ArticleRNA biology2026
The lncRNA ZNF295-AS1 alleviates lung squamous cell carcinoma progression by reducing miR-96-5p and inhibiting cancer cell invasiveness.
Article in RNA biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung squamous cell carcinoma (LUSC) is highly invasive, and patients with advanced disease generally have a poor prognosis. ZNF295-AS1 is abnormally expressed in lung cancer. This study aims to investigate the prognostic value of ZNF295-AS1 in LUSC and its potential regulatory mechanisms. This study enrolled 116 patients with lung upper-segment carcinoma (LUSC) and obtained LUSC tissue and adjacent normal tissue during surgery. RT-qPCR was used to assess the expression levels of ZNF295-AS1 and miR-96-5p in tissues and cell lines. Cox proportional hazards analysis identified independent factors affecting LUSC prognosis. CCK-8 and Transwell assays assessed cellular proliferation, invasion, and migration capabilities, respectively. DLR validated the relationship between ZNF295-AS1 and miR-96-5p. Compared with normal tissue and BEAS-2B cells, ZNF295-AS1 is significantly downregulated in LUSC tissue and cells. ZNF295-AS1 negatively regulates miR-96-5p level by binding to it as a target. ZNF295-AS1 serves as a protective factor influencing LUSC prognosis. Furthermore, elevating ZNF295-AS1 levels reduces miR-96-5p expression in cells, thereby diminishing the proliferation, migration, and invasion capabilities of LUSC cell lines and mitigating LUSC progression. ZNF295-AS1 demonstrates significant prognostic value in clinical settings for LUSC and holds promise as a novel prognostic biomarker. ZNF295-AS1 acts as a protective factor against LUSC. Mechanistically, ZNF295-AS1 alleviates LUSC progression and improves patient prognosis by regulating miR-96-5p levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.